Morgan Stanley has an overweight rating on JSW Steel with the target price at Rs 1,300. Analysts said that along with JFE’s technological expertise, JSW is looking to leverage its project execution capabilities to participate in multi-decade growth opportunities. Under a new pact between JFE and JSW, JFE will invest about Rs 15,800 crore in…
Bharat Taxi gears up to rival Ola, Uber, Rapido app – Will be better for drivers, passengers? Check salient features MSN Source link
Bharat Taxi gears up to rival Ola, Uber, Rapido app – Will be better for drivers, passengers? Check salient features ET Now Source link
Bharat Taxi Begins Pilot Operation In Delhi To Rival Ola, Uber With Fair Fares, Zero Commission | Check Key Features thedailyjagran.com Source link
BofA Securities has a neutral rating on PB Fintech (Policybazar) with the target price of Rs 1,980. Analysts said that the company’s management sees no GST-led negative impact on health and term policies, some impact on savings business but they’re working to address the same in the next 3-6 months. Most insurer contracts on combined…
Bharat Taxi gears up to rival Ola, Uber, Rapido app – Will be better for drivers, passengers? Check salient features ET Now Source link
What is Bharat Taxi? Govt launches ride-hailing service to take on Ola, Uber in THESE cities; check key details DNA India Source link
‘Bharat Taxi’ set to take on Ola, Uber, Rapido; Check out the key features of the ride-hailing app MSN Source link
The central government has started pilot trials for its ride hailing service, ‘Bharat Taxi’, set to take on the already existing and popular ones, Ola, Uber, Rapido and others. The service is aimed at offering an alternative for drivers of these private commercial services. Bharat taxi is driver-oriented taxi service The central government has started…
HSBC has a buy on Dr Reddys Labs with the target price at Rs 1,430. Analysts said that the semaglutide opportunity is intact for Dr Reddy’s in Canada, and it has replied to Health Canada’s queries on its application. GLP-1 drugs class remains the company’s focus segment and it is making progress in long-term drivers…